YOLFTbeta
Xenetic Biosciences Inc

Xenetic Biosciences Inc

XBIO · NASDAQ · Healthcare / Biotechnology

1.66USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.66
Open1.77
Day Range1.66 – 1.84
52-Week Range1.87 – 13.93
Volume9.71K
Market Cap5.30M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.15
Dividend Yield0.00%
Beta2.24
50-Day Avg3.24
200-Day Avg2.86

About

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. James F. Parslow
  • Employees2
  • Headquarters945 Concord Street, Framingham, MA, United States, 01701, USA
  • Websitehttps://www.xeneticbio.com

Leadership

  • Mr. James F. ParslowCFO, COO, Interim CEO & Corporate Secretary · b. 1965

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue293.60K1.00M003.00M7.58M017.07K436.94K1.16M1.71M2.54M2.50M2.98M
Growth (%)-+240.60%-100.00%--+152.83%-100.00%-+2460.31%+165.64%+47.06%+48.80%-1.56%+19.04%
Cost of Revenue44.84K8.44K056.12K36.45K156.12K15.83K--35.48K27.04K---
Gross Profit248.76K991.57K0-56.12K2.96M7.43M-15.83K17.07K436.94K1.16M1.71M2.54M2.50M2.98M
Gross Margin84.73%99.16%--98.79%97.94%-100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense6.59M9.61M12.92M9.77M50.39M11.00M7.26M12.90M14.37M6.91M8.42M7.06M6.70M5.81M
Operating Income-6.34M-8.61M-12.92M-9.82M-47.43M-3.57M-7.28M-12.89M-13.94M-5.75M-6.72M-4.52M-4.20M-2.83M
Operating Margin-2160.83%-861.35%---1581.02%-47.05%--75511.71%-3189.82%-495.12%-393.57%-177.79%-168.16%-95.23%
EBITDA-5.04M-8.53M-14.21M-9.77M-53.44M-3.57M-7.26M-9.58M-4.67M-5.61M-6.53M-4.13M-3.81M-2.68M
EBITDA Margin-1716.61%-852.66%---1781.34%-47.06%--56111.35%-1067.81%-483.31%-382.28%-162.78%-152.26%-90.07%
Net Income-6.33M-8.58M-14.31M-12.51M-54.21M-3.60M-7.30M-12.78M-10.89M-5.65M-6.55M-4.13M-3.96M-2.68M
Net Income Margin-2155.41%-857.92%---1806.87%-47.40%--74856.59%-2493.11%-486.36%-383.87%-162.78%-158.39%-90.07%
R&D1.94M3.06M6.32M3.43M43.74M4.06M2.88M4.89M1.73M3.16M4.77M3.49M3.29M3.07M
R&D as % of Total Revenue661.95%306.03%--1457.93%53.53%-28649.60%396.26%272.55%279.50%137.59%131.52%102.99%
Interest Expense51.74K6324.71K267.00K729.57K1.82K24.13K111.80K18.36M101.59K165.56K---
Interest Expense % of Total Revenue17.62%0.06%--24.32%0.02%-655.13%4202.06%8.75%9.70%---

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets222.50K25.37M19.47M16.32M16.91M20.97M19.16M14.43M21.55M13.18M19.82M14.72M10.61M6.90M8.36M
Total Liabilities220.74K4.59M6.85M5.84M10.30M4.80M4.86M4.52M4.33M963.97K1.42M1.07M809.59K894.26K968.02K
Total Equity1.76K20.78M12.62M10.48M6.61M16.17M14.30M9.91M17.21M12.22M18.39M13.65M9.80M6.01M7.40M
Cash10.00K11.14M4.84M2.51M132.23K4.05M5.53M571.61K10.37M11.53M18.24M13.10M8.98M6.17M7.88M
Total Debt212.81K682.99K681.12K395.00K395.00K---20.04K62.52K27.04K----
Net Debt202.81K-10.45M-4.16M-2.11M262.77K-4.05M-5.53M-571.61K-10.35M-11.47M-18.22M-13.10M-8.98M-6.17M-7.88M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.26M-6.05M-12.33M-5.30M-8.79M1.49M-6.46M-6.40M-4.27M-4.74M-4.65M-4.11M-2.82M-2.29M
Investing Cash Flow-92.59K-144.63K-52.18K6.22K-16.79K-9.26K22.50K2.00K---500.00K---
Financing Cash Flow-303.35K2.09K9.82M3.00M12.72M1251.48M16.13M5.43M11.45M1.29M1614.00M
Capital Expenditure130.08K78.63K57.67K1.66K16.79K9.26K0000500.00K100
Free Cash Flow-6.39M-6.13M-12.39M-5.30M-8.80M1.48M-6.46M-6.40M-4.27M-4.74M-5.15M-4.11M-2.82M-2.29M
Dividends Paid----39.50M---------
FCF to OCF102.08%101.30%100.47%100.03%100.19%99.38%100.00%100.00%100.00%100.00%110.76%100.00%100.00%100.00%
Dividend Paid to FCF-----448.66%---------

Earnings

Report DateAug 31, 2012Nov 30, 2012Feb 28, 2013May 31, 2013Aug 31, 2013Mar 31, 2014Jun 30, 2014Nov 14, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Nov 15, 2016Mar 31, 2017May 15, 2017Aug 14, 2017Nov 14, 2017Mar 30, 2018May 15, 2018Aug 10, 2018Nov 9, 2018Mar 29, 2019May 13, 2019Aug 14, 2019Nov 14, 2019Mar 26, 2020May 14, 2020Aug 12, 2020Nov 12, 2020Mar 16, 2021May 11, 2021Aug 12, 2021Nov 12, 2021Mar 22, 2022May 12, 2022Aug 11, 2022Nov 9, 2022Mar 22, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 21, 2024May 9, 2024Aug 13, 2024Nov 12, 2024Mar 18, 2025May 7, 2025Aug 12, 2025Nov 12, 2025Mar 12, 2026May 13, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate--------79.20--------0.19-2.28-25.20-46.80-49.20---------0.38-3.70-2.20-1.30-0.20-1.30-1.60-1.20-0.15-1.10-1.20-1.80-0.09-1.10-1.13-1.12-0.87-0.79-0.83-0.14-0.20-0.72-0.64-0.49-0.52---
EPS Actual-15.05-4.254.42-4.01-22.32-118.26-80.30-79.20-122.33-69.12-31.99-151.00-94.92-93.35-734.55-3.48-6.84-40.80-40.80-31.20-0.26-0.26-0.26-0.26-2.09-0.26-0.26-2.67-0.20-1.90-1.50-1.42-0.16-1.50-1.30-1.30-0.14-1.20-1.90-0.60-0.10-0.60-0.69-0.69-0.77-0.78-0.83-0.28-0.68-0.59-0.45-0.33-0.22-0.20-0.41-
Surprise-------0.00%--------1731.58%-200.00%-61.90%12.82%36.59%--------47.37%48.65%31.82%-9.23%20.00%-15.38%18.75%-8.33%6.67%-9.09%-58.33%66.67%-11.11%45.45%38.94%38.39%11.49%1.27%0.00%-100.00%-240.00%18.06%29.69%32.65%57.69%---
Timing-------After-hours-------Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours---

Key Statistics & Ratios

Market Cap5.30M
Enterprise Value-613.81K
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales1.62
Price / Book0.96
EPS-1.15
Book Value3.23
Revenue (TTM)3.26M
Gross Profit (TTM)3.26M
EBITDA-5.75M
Profit Margin-75.91%
Operating Margin-147.09%
Return on Equity-47.04%
Return on Assets-26.80%
Shares Outstanding2.34M
Shares Float1.89M
Beta2.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 40.00
  • Hold
    1

Ownership Breakdown

Institutions
6.49%
Insiders
11.43%
Retail / Other
82.08%

Top Institutional Holders

  • Renaissance Technologies Corp
    137.44K6.00%
  • Geode Capital Management, LLC
    21.44K0.94%
  • Vanguard Capital Management, LLC
    6.73K0.29%
  • JTC Employer Solutions Trustee Ltd
    2.70K0.12%
  • Tower Research Capital LLC
    8060.04%
  • Harwood Advisory Group, LLC
    20.00%
  • DRW Securities, LLC
    00.00%
  • Morgan Stanley - Brokerage Accounts
    00.00%
  • Citigroup Inc
    00.00%
  • Bank of America Corp
    00.00%
  • Citadel Advisors Llc
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    10.49K0.45%
  • Fidelity Series Total Market Index
    1.39K0.06%
  • Fidelity Nasdaq Composite Index
    1.29K0.05%

Stock Splits

  • May 15, 20231:10
  • Jun 25, 20191:12